Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Podcast 36: CDMOs/CMOs Ramp Up Biomanufacturing Capacity

Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding?

Key topics: (see Chapter Markers in drop down menu in audio player above)

  • A roundup of expansion activity (1:12)
  • Fujifilm Diosynth Biotechnologies (1:21)
  • Samsung Biologics (5:02)
  • Lonza (6:44)
  • Boehringer Ingelheim (10:00)
  • Thermo Fisher Scientific (10:37)
  • Catalent (13:59)
  • WuXi Biologics (17:32)

Sponsor: BIOVECTRA

Links:

Subscribe to our e-newsletter at www.dcatvci.org

Follow us on Twitter @DCATvci

Support the show 

You May Also Like

Podcast 44: What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights…

Podcast 43: CDMOs/CMOs: The Movers and Shakers of 2023

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the…

Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an…

Podcast 41: API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains 

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages…